MyFinsight
Home
Blog
About
Net (loss) income
-$10,496M
(-635.51%↓ Y/Y)
US
$5,601M
(11.18%↑ Y/Y)
Europe
$1,155M
(-1.95%↓ Y/Y)
Rest Of World
$872M
(4.06%↑ Y/Y)
Europe
$169M
(1590.00%↑ Y/Y)
Rest Of World
$4M
(0.00%↑ Y/Y)
US
$2M
(-84.62%↓ Y/Y)
(loss) income before
income taxes
-$10,254M
(-522.15%↓ Y/Y)
Income tax expense
$242M
(-48.29%↓ Y/Y)
Other (income)
expense, net
$387M
(86.06%↑ Y/Y)
Product
$7,627M
(8.12%↑ Y/Y)
Royalty Contract And
Other
$176M
(551.85%↑ Y/Y)
Operating (loss) income
-$10,394M
(-520.13%↓ Y/Y)
Total revenues
$7,803M
(10.18%↑ Y/Y)
Interest expense
$247M
(-2.76%↓ Y/Y)
Total costs and
expenses
$18,197M
(294.90%↑ Y/Y)
Acquired in-process
research and development...
$11,183M
(18232.79%↑ Y/Y)
Selling, general and
administrative expenses
$1,921M
(40.73%↑ Y/Y)
Research and development
expenses
$1,764M
(18.31%↑ Y/Y)
In-process research and
development impairments
$1,750M
(821.05%↑ Y/Y)
Cost of goods sold
$1,579M
(5.20%↑ Y/Y)
Back
Back
Income Statement
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)
source: myfinsight.com